Long-Term Strategies in Advanced HCC
Long-Term Strategies in Advanced HCC
May 2016
- A 70-year old male with metastatic HCC involving the lung and bone confirmed by biopsy, experiencing mild bone pain
- ECOG=1
- Child-Pugh A
- Therapy was initiated with sorafenib at 400 BID
- Patient experienced grade 1 HTN and grade 1 hand-foot skin reaction, which was managed effectively
April 2017
- Documented radiographic progression
- Therapy with regorafenib at 160mg was initiated
- Patient experienced grade 1 HTN, grade 2 hand-foot skin reaction
Hope Beyond Surgery: Optimizing Care for Cholangiocarcinoma
February 15th 2024In an interview for Cholangiocarcinoma Awareness Day, Domenech Asbun, MD, discussed how the management of cholangiocarcinoma continues to evolve and addressed unmet needs in early detection and systemic therapy.
Read More
Durvalumab/Bevacizumab/TACE Significantly Extends Survival in HCC
February 6th 2024In an interview with Targeted Oncology, Bruno Sangro, MD, PhD, discussed the potential durvalumab, bevacizumab, and TACE has to set a new standard-of-care among patients with unresectable hepatocellular carcinoma.
Read More
Regorafenib Discontinuation More Likely With Poor Liver Function in Liver Cancer
January 19th 2024Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious adverse effects leading to regorafenib treatment discontinuation, researchers have found.
Read More
